OakChart

Pulmatrix Inc

PULMHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.31-0.04 (-2.96%)
2026-11-11 22:13 CET
Market cap
4.93 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-4.03 USD m
Free cash flow, TTM
-3.91 USD m
EPS diluted, TTM
-1.10
P/E
-
Compare

Price

PULM against its 20, 50 and 200-day averages
2050200earnings
1.002.003.00703K1.4MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PULMclose 1.3120-day 1.4250-day 1.46200-day 1.661.3152w low

73.7% under the 52-week high of 4.98 on 17 Nov 2025. 52-week low 1.06 on 4 Nov 2026. Last 15 sessions, 47.2% high to low

Volume 0.13× normal · the line is the 50-bar volume average

Profile

PULM
52-week range, 6% of the way up
1.064.98

Pulmatrix, Inc. is a clinical stage biotechnology company, which engages in the development and discovery of novel inhaled therapeutics products. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov, and Robert S. Langer, Jr. in April 2003 and is headquartered in Framingham, MA.

Employees2
IPOMar 21, 2014
Beta1.92
ATR, 14d0.14
Rel volume0.13
Short float1.08%
Insider own0.00%
Inst own9.13%

Snapshot

6 groups

Valuation

Index-
Market Cap4.78M
Enterprise Value2.88M
Income-4.03M
Sales0.00M
Book/sh0.44
Cash/sh0.79
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees2
IPOMar 21, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B3.01
P/C1.67
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio4.70
Current Ratio4.70
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.10
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y36.28% 36.26%
Sales past 3/5Y- -
EPS Y/Y TTM49.19%
Sales Y/Y TTM-100.00%
EPS Q/Q32.09%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.- -

Ownership

Insider Own0.00%
Insider Trans-
Inst Own9.13%
Inst Trans0.79%
ROA-85.40%
ROE-98.35%
ROIC-156.94%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-7.68%
SMA50-10.52%
SMA200-21.32%
Trades-

Technical

Shs Outstand3.65M
Shs Float3.65M
Short Float1.08%
Short Ratio1.20
Short Interest0.04M
52W High4.98 -73.69%
52W Low1.06 23.58%
Volatility17.96% 10.57%
ATR (14)0.14
RSI (14)41.57
Beta1.92
Rel Volume0.13
Avg Volume32.87K
Volume4,124

Performance

Perf Week-13.82%
Perf Month-5.07%
Perf Quarter-13.25%
Perf Half Y3.15%
Perf YTD-41.26%
Perf Year-73.02%
Perf 3Y-24.71%
Perf 5Y-91.71%
Perf 10Y-99.28%
Recom1.00
Target Price10.00
Prev Close1.35
Price1.31
Change %-2.96%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Feb 09, 2018InitiatedHH.C. WainwrightBuy$5+281.7%

Peers

Mkt cap
TickerCompanyMkt cap
SVRASavara Inc1.10B
AVLNAvalyn Pharma Inc1.40B
TELOTelomir Pharmaceuticals Inc43.68M
JUNSJupiter Neurosciences Inc2.82M
SERSerina Therapeutics Inc38.35M
MNKDMannkind Corp1.35B
CLNNClene Inc60.40M
CRVOCervoMed Inc26.78M
ANVSAnnovis Bio Inc36.58M
PLRXPliant Therapeutics Inc48.15M

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Are MGLD, NRIM, PULM Obtaining Fair Deals for their Shareholders? (PR Newswire)
  • Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger (PR Newswire) -5.63%
  • Pulmatrix Announces First Quarter 2026 Financial Results (PR Newswire)
  • Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger (PR Newswire)
  • Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan (PR Newswire) -28.77%
  • Wave crashes on obesity drug update; Kodiaks reboot pays dividends (BioPharma Dive)
  • Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction (TipRanks) +9.52%
  • Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities (PR Newswire) -36.79%
  • Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results (PR Newswire) -9.35%
  • Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives (PR Newswire) -8.15%
  • Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets (PR Newswire)
  • Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets (PR Newswire)
  • Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets (PR Newswire) +6.55%
  • Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-05-15---0.320---
2025Q32025-10-16-0.240--0.00--
2025Q22025-08-06---0.420---
2024Q42025-03-21-0.550--0.5440.00--
2024Q32024-11-08-0.710--0.7080.37--
2024Q22024-08-13-1.590--1.5911.55--
2024Q12024-05-100.230-0.2265.89--
2023Q42024-03-28-0.580-1.040-0.5702.211.801
2023Q32023-11-09-1.030-1.050-1.0331.751.861
2023Q22023-08-10-1.040-1.230-1.0451.841.511
2023Q12023-05-12-1.220--1.2181.50--
2022Q42023-03-30-1.140-1.440-1.1591.711.871
2022Q32022-11-10-1.450-1.510-1.4531.871.161
2022Q22022-08-08-1.360-1.510-1.3631.331.161
2022Q12022-05-12-1.510-1.410-1.5081.161.071
2021Q42022-03-29-2.430-1.600-2.2430.461.181

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2013FY-765-675-765-0.00
2014FY-278--0.00-
2015FY-646-550-6461.201.30
2016FY-376--3760.84-
2017FY-186-188-1860.340.30
2018FY-99.600-118-99.6660.150.00
2019FY-24.600-17.800-24.6167.916.23
2020FY-13.400-16.400-13.43012.6310.60
2021FY-8.630-7.800-8.6275.175.89
2022FY-5.460-5.760-5.4636.076.24
2023FY-3.870-4.340-3.8677.306.90
2024FY-2.620--4.9807.81-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2025FYS2024-03-271007.017.017.01
2025FYS2024-03-261007.017.017.01
2025FYS2024-03-251007.017.017.01
2025FYS2024-03-241007.017.017.01
2025FYS2024-03-231007.017.017.01
2025FYS2024-03-221007.017.017.01
2025FYS2024-03-211007.017.017.01
2025FYE2024-03-27100-4.95-4.95-4.95
2025FYE2024-03-26100-4.95-4.95-4.95
2025FYE2024-03-25100-4.95-4.95-4.95
2025FYE2024-03-24100-4.95-4.95-4.95
2025FYE2024-03-23100-4.95-4.95-4.95
2025FYE2024-03-22100-4.95-4.95-4.95
2025FYE2024-03-21100-4.95-4.95-4.95

Estimate history

EPS, annual-186-99.666-24.616-13.43-8.627-5.463-3.867-2.617-1.413-1.1031
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.591-0.708-0.544-0.495-0.424-0.24-0.254-0.321-0.288
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.3350.1537.9112.6345.1696.0717.2987.80600
Period201720182019202020212022202320242025TTM
Sales, quarterly1.5520.3660.003000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.1050.24711.8053.2223.6393.6523.6523.6523.652
Period201720182019202020212022202320242025MRQ
Shares, quarterly3.6523.6523.6523.6523.6523.6523.6523.6523.652
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.007.817.306.075.1712.637.910.15
Cost of Goods Sold Incl. D&A0.000.000.431.481.54----
Gross Profit0.000.007.375.824.53----
Selling, General and Administrative Excl. Other4.115.1714.5220.5623.4720.5221.4520.5720.25
Research and Development0.010.047.0615.3818.0815.2115.3912.6612.97
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-4.11-5.17-7.14-14.74-18.95-16.59-9.86-13.42-20.33
Interest Expense0.000.000.000.000.000.000.000.000.19
Unusual Expense0.00-0.070.070.000.003.589.297.270.07
Net Income Before Taxes-4.01-5.16-9.56-14.12-18.84-20.17-19.31-20.60-20.56
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-4.01-5.16-9.56-14.12-18.84-20.17-19.31-20.60-20.56
Net Income From Continuing Operations-4.01-5.16-9.56-14.12-18.84-20.17-19.31-20.60-20.56
Net Income-4.03-5.16-9.56-14.12-18.84-23.37-19.31-20.60-20.56
EPS (Recurring)-1.10-1.43-2.60-3.87-5.46-7.70-8.91-18.54-99.44
EPS (Basic, Before Extraordinaries)-1.10-1.41-2.62-3.87-5.46-8.63-13.43-24.62-99.67
EPS (Diluted)-1.10-1.41-2.62-3.87-5.46-8.63-13.43-24.62-99.67
EBITDA-4.11-5.17-6.71-13.27-17.40-15.35-8.82-12.66-20.10
Non-Operating Income (Expense)0.10-0.06-2.350.620.11-0.00-0.160.100.02
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.020.030.510.951.111.161.162.072.97
Price To Sales Ratio--3.270.932.204.592.711.8264.75
Gross Margin--94.4379.7974.55----
Operating Margin---91.53-201.97-312.09-320.95-78.06-169.71-13,288.24
Net Margin---122.46-193.49-310.26-452.08-152.83-260.38-13,439.87
Shares Outstanding3.653.653.653.653.643.221.811.000.25
Market Capitalization4.934.9325.496.7914.1228.2042.9717.2011.84

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.37
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.00--
Gross Profit0.000.000.000.000.000.00--
Selling, General and Administrative Excl. Other1.051.290.910.871.551.851.963.02
Research and Development0.000.00-0.000.010.010.020.010.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-1.05-1.29-0.91-0.87-1.55-1.85-1.95-2.66
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.00-0.00-0.070.070.00
Net Income Before Taxes-1.04-1.17-0.93-0.88-1.55-1.81-1.99-2.59
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-1.04-1.17-0.93-0.88-1.55-1.81-1.99-2.59
Net Income From Continuing Operations-1.04-1.17-0.93-0.88-1.55-1.81-1.99-2.59
Net Income-1.05-1.17-0.93-0.88-1.55-1.81-1.99-2.59
EPS (Recurring)-0.29-0.32-0.25-0.24-0.42-0.51-0.53-0.71
EPS (Basic, Before Extraordinaries)-0.29-0.32-0.25-0.24-0.42-0.49-0.54-0.71
EPS (Diluted)-0.29-0.32-0.25-0.24-0.42-0.49-0.54-0.71
EBITDA-1.05-1.29-0.91-0.87-1.55-1.85-1.95-2.66
Non-Operating Income (Expense)0.010.12-0.02-0.01-0.00-0.030.030.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.000.000.010.010.010.010.010.20
Price To Sales Ratio---5,916.7068.2912.663.270.78
Operating Margin-------65,066.67-725.96
Net Margin-------66,200.00-706.83
Shares Outstanding3.653.653.653.653.653.653.653.65
Market Capitalization4.934.718.1417.7525.2024.3225.497.82

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments4.099.5219.1735.7853.8431.6623.442.563.55
Short Term Receivables0.000.000.931.300.070.087.200.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.040.400.741.070.870.720.740.690.67
Total Current Assets4.139.9220.8438.1554.7832.4631.393.254.22
Net Property, Plant & Equipment0.000.0011.470.942.411.850.900.390.61
Total Investments and Advances0.010.011.471.471.620.200.200.200.20
Intangible Assets0.00---0.003.583.5810.8510.91
Other Assets0.000.010.180.390.000.000.030.030.03
Total Assets4.149.9433.9640.9558.8238.0936.1014.7215.98
Short Term Debt Incl. Current Port. of LT Debt0.000.000.430.861.431.140.680.003.22
Accounts Payable0.270.811.921.190.840.850.601.180.46
Other Current Liabilities0.060.121.562.982.176.1915.931.702.16
Total Current Liabilities0.330.933.915.024.448.1817.202.885.84
Long Term Debt0.000.008.330.000.860.610.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.073.734.826.076.177.880.000.00
Total Liabilities0.331.0015.969.8411.3714.9625.082.885.84
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.001.080.000.000.000.00
Common Equity3.818.9518.0031.1146.3723.1411.0211.8410.14
Total Shareholders Equity3.818.9518.0031.1147.4523.1411.0211.8410.14
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity3.818.9518.0031.1147.4523.1411.0211.8410.14
Total Liabilities & Stockholders Equity4.149.9433.9640.9558.8238.0936.1014.7215.98
Book Value Per Share1.042.454.938.5514.3912.8211.0248.0296.32
Tangible Book Value Per Share1.042.454.938.5514.3910.847.444.05-7.38
Full-Time Employees2222292520222224
Price to Book Ratio3.102.330.340.400.611.861.561.002.25
Return on Assets-73.31-43.55-37.70-37.76-41.60-52.05-81.05-133.96-110.63
Return on Equity-80.93-70.96-57.51-47.95-57.15-113.05-180.17-187.10-191.09
Return on Invested Capital-135.49-106.84-53.65-60.55-41.76-81.31-186.91-173.62-178.12
Quick Ratio12.5510.685.337.6012.333.971.821.130.72
Current Ratio12.5510.685.337.6012.333.971.821.130.72

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-4.01-5.16-9.56-14.12-18.84-20.17-19.31-20.60-20.56
Depreciation-0.000.431.481.541.241.040.770.23
Other Funds (Non Cash)0.02-0.043.200.961.114.7410.459.333.09
Funds from Operations-4.00-5.20-5.93-11.68-16.18-14.20-7.82-10.50-17.25
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital0.09-0.23-4.79-4.30-3.18-5.53-4.6713.730.48
Cash from Operating Activities-3.91-5.43-10.72-15.98-19.36-19.73-12.483.23-16.76
Capital Expenditures0.000.00-0.40-0.68-0.09-0.14-0.28-0.06-0.02
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.00-0.40-0.68-0.09-0.14-0.28-0.06-0.02
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock0.950.000.000.051.2343.4820.9817.7019.30
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.950.000.000.051.2343.4820.9817.7019.30
Proceedsfrom Stock Options0.950.000.000.001.2343.277.310.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.00-3.50
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.620.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.620.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities0.950.000.000.051.2343.4820.9817.7015.79
Net Change in Cash-2.96-5.43-11.11-16.61-18.2123.608.2220.88-0.99
Free Cash Flow-3.91-5.43-11.11-16.66-19.44-19.87-12.763.17-16.78
Preferred Dividends (Cash Flow)-0.000.000.000.00-0.000.000.00
Price to Free Cash Flow-------4.54-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2.874.024.094.795.837.71
Short Term Receivables0.000.000.000.000.000.02
Inventories0.000.000.000.000.000.00
Other Current Assets0.370.470.040.180.320.32
Total Current Assets3.244.494.134.976.148.04
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.010.010.010.010.010.01
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets3.254.504.144.986.158.05
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.530.650.270.070.380.66
Other Current Liabilities0.160.250.060.180.160.25
Total Current Liabilities0.690.910.330.250.550.90
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities0.690.910.330.250.550.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.970.950.000.000.000.00
Common Equity1.592.643.814.735.607.15
Total Shareholders Equity2.563.593.814.735.607.15
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity2.563.593.814.735.607.15
Total Liabilities & Stockholders Equity3.254.504.144.986.158.05
Book Value Per Share0.440.721.041.301.531.96
Tangible Book Value Per Share0.440.721.041.301.531.96
Full-Time Employees--2---
Price to Book Ratio3.101.241.723.173.532.72
Return on Assets-85.40-72.14-73.31-75.43-72.31-63.43
Return on Equity-98.35-84.30-80.93-79.47-83.85-93.19
Return on Invested Capital-40.52-32.64-24.36-18.53-27.64-25.30
Quick Ratio4.704.9612.5519.9711.218.90
Current Ratio4.704.9612.5519.9711.218.90

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.04-1.17-0.93-0.88-1.55-1.81
Depreciation--0.000.000.000.00
Other Funds (Non Cash)0.000.000.010.010.01-0.06
Funds from Operations-1.03-1.17-0.92-0.87-1.54-1.87
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.070.100.22-0.16-0.340.05
Cash from Operating Activities-1.11-1.07-0.71-1.03-1.88-1.81
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock-0.051.000.000.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.051.000.000.000.000.00
Proceedsfrom Stock Options-0.051.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.051.000.000.000.000.00
Net Change in Cash-1.16-0.07-0.71-1.03-1.88-1.81
Free Cash Flow-1.11-1.07-0.71-1.03-1.88-1.81

Revenue breakdown

Total Pharmaceutical Preparations revenue2024: 7.81M
United States2024: 7.81M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.08%0.0M3.7M26.96K
2026-10-151.18%0.0M3.7M23.99K
2026-09-301.34%0.0M3.7M26.40K
2026-09-151.52%0.1M3.7M49.63K
2026-08-310.55%0.0M3.7M47.41K
2026-08-140.11%0.0M3.7M48.80K
2026-07-310.46%0.0M3.7M49.17K
2026-07-150.75%0.0M3.7M55.11K
2026-06-302.50%0.1M3.7M54.13K
2026-06-150.27%0.0M3.7M41.90K
2026-05-290.68%0.0M3.7M50.49K
2026-05-150.93%0.0M3.7M51.18K
2026-04-301.11%0.0M3.7M50.45K
2026-04-150.54%0.0M3.7M45.19K
2026-03-310.22%0.0M3.7M44.03K
2026-03-130.07%0.0M3.7M32.83K
2026-02-270.08%0.0M3.7M20.84K
2026-02-130.12%0.0M3.7M18.44K
2026-01-300.11%0.0M3.7M17.83K
2026-01-150.19%0.0M3.7M17.90K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-09425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-30425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-278-KCurrent report2026-10-26SEC
2026-10-26424B3SEC
2026-10-22EFFECTEffectiveness filing by commission orderSEC
2026-10-22425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-13425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-10-07424B3SEC
2026-10-07DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-05ARSAnnual report to security holders. 2025-12-31SEC
2026-10-05S-3/ASEC
2026-09-25EFFECTEffectiveness filing by commission orderSEC
2026-09-25424B3SEC
2026-09-25DEFM14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-23S-4/ASEC
2026-09-22425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-09-17S-4/ASEC
2026-09-04S-4/ASEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-07S-3/ASEC
2026-08-03S-4/ASEC
2026-07-09S-4Registration statement for securities to be issued in business combination transactionsSEC
2026-06-1610-K/A2025-12-31SEC
2026-06-05425Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions.SEC
2026-06-04S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-158-KCurrent report2026-05-15SEC
2026-05-14DRSSEC
2026-04-22SCHEDULE 13DSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RENAISSANCE TECHNOLOGIES LLC3.36%
BlackRock, Inc.1.50%
GEODE CAPITAL MANAGEMENT, LLC0.91%
VANGUARD CAPITAL MANAGEMENT LLC0.88%
SBI Securities Co., Ltd.0.83%
Shay Capital LLC0.52%
VANGUARD FIDUCIARY TRUST CO0.40%
STATE STREET CORP0.38%
XTX Topco Ltd0.33%
UBS Group AG0.00%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.88%
Fidelity Extended Market Index Fund0.50%
Fidelity Series Total Market Index Fund0.14%
Fidelity Total Market Index Fund0.12%
Fidelity Nasdaq Composite Index Fund0.09%

OakChart. PULM. Cached 15 minutes.

Some panels did not load: insider.